2012 news releases and statements

10/12/2012
Stephen Whitehead appointed HCA President: A new era for healthcare communications
10/12/2012
ABPI responds to Government’s annual update on Life Sciences Strategy
06/12/2012
ABPI position on transparency in clinical trial results
06/12/2012
ABPI comment on transparency in clinical trial results
05/12/2012
ABPI Chief Executive responds to Chancellor's Autumn Statement
03/12/2012
ABPI Chief Executive comments on new study on pharmaceutical R&D costs
26/11/2012
ABPI signs up to joint UK statement on the revision of the EU trials legislation
22/11/2012
Partners in healthcare join to reverse decline in clinical research in UK
22/11/2012
New report demonstrates more ‘joined-up’ approach needed to deliver Life Sciences strategy
21/11/2012
Research-based pharmaceutical industry welcomes ‘highest ever’ R&D spend in Northern Ireland
14/11/2012
ABPI statement on 2020 Health publication 'Orphan medicines: special treatment required?'
12/11/2012
ABPI statement on George Osborne’s speech at the Royal Society
08/11/2012
Social contract between NHS and pharmaceutical industry is breaking down
05/11/2012
ABPI appoints first dedicated Northern Ireland Director
31/10/2012
Spending on new medicines is declining in England
25/10/2012
ABPI statement on changes to Patents Act
23/10/2012
New reports find UK medicine costs firmly under control
19/10/2012
ABPI statement on animal research poll commissioned by the Department for Business, Innovation and Skills
17/10/2012
Patients in half of disease areas still not receiving cost-effective NICE approved medicines
20/09/2012
ABPI statement on industry investment in Alzheimer's treatment
04/09/2012
ABPI statement on the appointment of Jeremy Hunt as Secretary of State for Health
30/08/2012
General public has fundamental misunderstanding of cost and value of medicines
28/08/2012
Warm welcome from ABPI on Innovation Scorecard
21/08/2012
Shire joins the ABPI
15/08/2012
ViroPharma Incorporated joins the ABPI
14/08/2012
ABPI publishes guidelines for phase 1 clinical trials
13/08/2012
Fresenius Medical Care joins the ABPI
08/08/2012
ABPI announces team to negotiate next pricing scheme
03/08/2012
ABPI and DH publish statement on arrangements for pricing branded medicines from 2014
02/08/2012
Pharmaceutical industry welcomes PM’s support for life sciences
02/08/2012
ABPI response to the announcement of the first Biomedical Catalyst awards
24/07/2012
Cautious ABPI welcome for new NICE powers on orphan medicines
23/07/2012
New Medical, Innovation and Research Director completes Whitehead’s top team
18/07/2012
ABPI welcomes European Commission proposals to revamp rules on clinical research
02/07/2012
Concern as NHS spending on most advanced medicines set to decline over next three years
27/06/2012
Phase I clinical trials insurance guidance published
22/06/2012
ABPI Scotland welcomes commitment to boost innovation in NHS
21/06/2012
ABPI takes stand against medicine’s money wasting middle-men
15/06/2012
PPRS Dispute Resolution Panel’s decisions published
06/06/2012
'I fear for the future of UK medical research,' says head of the UK pharmaceutical industry
23/05/2012
Health and life sciences group agrees new clinical trials transparency principles
16/05/2012
ABPI launches guide to set up joint working projects
15/05/2012
ABPI response to the publication of the APPG report on supply shortages
11/05/2012
ABPI develops Medical and Innovation capability
30/04/2012
New ABPI President appointed
26/04/2012
ABPI launches Regional Partnership team to improve patient health
26/04/2012
Is saving money more important than saving lives?
18/04/2012
The pharmaceutical industry and education: the benefits of partnership
29/03/2012
Healthcare community agree on principles for working together to improve patient health
22/03/2012
ABPI response to Budget 2012
22/03/2012
ABPI welcomes further investment in the UK
14/03/2012
Transporting animals for research purposes: the importance of high quality care and welfare
06/03/2012
ABPI appoints Catherine Meaden as Head of Policy and Public Affairs
05/03/2012
Can we afford innovation in medicine?
29/02/2012
ABPI welcomes UK plan for rare disease
23/02/2012
Department of Health report shows UK medicines are good value for money
22/02/2012
Innovation and commercial success
07/02/2012
ABPI hires Luther Pendragon for public affairs support
02/02/2012
ABPI response to AstraZeneca restructuring initiatives
06/01/2012
New look for science resources website will help teachers and students
04/01/2012
Pharmaceutical industry leaders recognised in New Year Honours list

Print this page

Get in touch

Please choose the subject of your enquiry from the list below:

Enter the above code here:

Can't read? Try different words.

Submit

I am happy for ABPI to keep my details on file and to send me details of future ABPI work and services. ABPI will not sell your data to any third party or send you any information about products or services that ABPI has no direct connection with.

The Association of the British Pharmaceutical Industry

7th floor, Southside, 105 Victoria Street,
London, SW1E 6QT
Telephone +44 (0) 870 890 4333
ABPI Cymru Wales
ABPI Northern Ireland
ABPI Scotland

The Prescription Medicines Code of Practice Authority (PMCPA) is responsible for administering the ABPI Code of Practice for the Pharmaceutical Industry at arm's length of the ABPI itself.

The Office of Health Economics (OHE) provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.